Tafluprost Inhibitor

Name: Tafluprost Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5764457
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5764457

Tafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2alpha. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Tafluprost, Inhibitor

Full Product Name

Tafluprost

Product Synonym Names

AFP-168

Form/Format

Solid. Powder

Purity/Purification

97.70%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

452.53

Solubility

DMSO: 250mg/mL (552.45mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C25H33F2O5

SMILES

CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COc1ccccc1

CAS Number

209860-87-7

In Vitro

Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic pattern [1]. Tafluprost with reduced BAK has potential as a superior antiglaucoma drug, not only for its IOP-lowering effect but also for its good corneal safety profile [2]. Tafluprost single-use vials treatment,was effective in reducing IOP over the 3 years of this study, but visual field performance worsened by 10.3%-13.8% in patients with normal-tension glaucoma [3].

Product Categories/Family for Tafluprost, inhibitor

GPCR/G Protein; Prostaglandin Receptor; Immunology/Inflammation

Product References and Citations for Tafluprost, inhibitor

Kuwayama, Y. and A. Nomura, Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther, 2014. 31(4): p. 461-71.
Kuwayama, Y. and A. Nomura, Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther, 2014. 31(4): p. 461-71.
Kumagami, T., et al., Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions. J Ocul Pharmacol Ther, 2014. 30(4): p. 340-5.
Kumagami, T., et al., Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions. J Ocul Pharmacol Ther, 2014. 30(4): p. 340-5.
Inoue, K., A. Tanaka, and G. Tomita, Effects of tafluprost treatment, for 3 years in patients with normal-tension glaucoma. Clin Ophthalmol, 2017: p. 1411-6.
Inoue, K., A. Tanaka, and G. Tomita, Effects of tafluprost treatment, for 3 years in patients with normal-tension glaucoma. Clin Ophthalmol, 2013. 7: p. 1411-6.

Other Notes

Small volumes of Tafluprost, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Tafluprost purchase

MBS5764457 is an inhibitor targeting Tafluprost.